Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $472.17 million
- Book Value:
- Revenue TTM:
- $148.62 million
- Operating Margin TTM:
- Gross Profit TTM:
- $92.73 million
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Evolus Inc had its IPO on 2018-02-08 under the ticker symbol EOLS.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Evolus Inc has a staff strength of 215 employees.
Shares of Evolus Inc opened at $8.46 at the start of the last trading session i.e. 2023-03-19.
The stocks traded within a range of $8.28 - $8.67, and closed at $8.37.
This is a -1.41% slip from the previous day's closing price.
A total volume of 606,200 shares were traded at the close of the day’s session.
In the last one week, shares of Evolus Inc have slipped by -2.45%.
Evolus Inc's Key Ratios
Evolus Inc has a market cap of $472.17 million, indicating a price to book ratio of 14.6487 and a price to sales ratio of 2.9729.
In the last 12-months Evolus Inc’s revenue was $148.62 million with a gross profit of $92.73 million and an EBITDA of $-53853000. The EBITDA ratio measures Evolus Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Evolus Inc’s operating margin was -38.74% while its return on assets stood at -16.53% with a return of equity of -148.27%.
In Q4, Evolus Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 25.9%.
Evolus Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-1.32 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Evolus Inc’s profitability.
Evolus Inc stock is trading at a EV to sales ratio of 3.1296 and a EV to EBITDA ratio of -6.3881. Its price to sales ratio in the trailing 12-months stood at 2.9729.
Evolus Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- Total Liabilities
- Operating Cash Flow
- Capital Expenditure
- $2.29 million
- Dividend Payout Ratio
Evolus Inc ended 2023 with $177983.00 in total assets and $0 in total liabilities. Its intangible assets were valued at $177983.00 while shareholder equity stood at $18499.00.
Evolus Inc ended 2023 with $0 in deferred long-term liabilities, $46509.00 in other current liabilities, 1.00 in common stock, $-497294.00 in retained earnings and $21208.00 in goodwill. Its cash balance stood at $53922.00 and cash and short-term investments were $53922.00. The company’s total short-term debt was $1,320 while long-term debt stood at $71.88 million.
Evolus Inc’s total current assets stands at $100802.00 while long-term investments were $0 and short-term investments were $0. Its net receivables were $22448.00 compared to accounts payable of $33729.00 and inventory worth $18852.00.
In 2023, Evolus Inc's operating cash flow was $-1391000.00 while its capital expenditure stood at $2.29 million.
Comparatively, Evolus Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Evolus Inc stock is currently trading at $8.37 per share. It touched a 52-week high of $14.34 and a 52-week low of $14.34. Analysts tracking the stock have a 12-month average target price of $16.56.
Its 50-day moving average was $9.22 and 200-day moving average was $9.49 The short ratio stood at 3.16 indicating a short percent outstanding of 0%.
Around 2420.1% of the company’s stock are held by insiders while 5817% are held by institutions.
Frequently Asked Questions About Evolus Inc
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It serves self-pay aesthetic healthcare market. Evolus, Inc. was incorporated in 2012 and is headquartered in Newport Beach, California.